Compare Stocks Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections 5 Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:EXELNASDAQ:HALONASDAQ:RGENNASDAQ:SYNH Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEXELExelixis$21.23+0.5%$22.87$18.64▼$24.34$6.40B0.572.30 million shs2.00 million shsHALOHalozyme Therapeutics$45.39-0.9%$40.47$31.86▼$46.16$5.83B1.26977,144 shs1.04 million shsRGENRepligen$171.03-2.8%$176.65$110.45▼$211.13$9.84B1.03518,582 shs430,952 shsSYNHSyneos Health$42.98+0.0%$42.86$22.89▼$52.23$4.46B1.581.92 million shs7.39 million shsIncluded in your MarketBeat subscription Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Download This ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEXELExelixis+0.52%-2.44%-6.97%+3.66%+10.29%HALOHalozyme Therapeutics-0.94%+3.54%+18.26%+25.73%+35.65%RGENRepligen-2.84%+3.72%+4.18%-17.94%+11.76%SYNHSyneos Health0.00%0.00%0.00%0.00%+3.47%MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEXELExelixis4.9233 of 5 stars3.32.00.04.31.93.34.4HALOHalozyme Therapeutics4.6686 of 5 stars2.41.00.04.42.72.54.4RGENRepligen4.2319 of 5 stars2.42.00.04.53.42.51.9SYNHSyneos HealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEXELExelixis2.59Moderate Buy$26.1323.06% UpsideHALOHalozyme Therapeutics2.83Moderate Buy$53.1417.08% UpsideRGENRepligen2.89Moderate Buy$197.7515.62% UpsideSYNHSyneos HealthN/AN/AN/AN/ACurrent Analyst RatingsLatest EXEL, HALO, RGEN, and SYNH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024EXELExelixisStephens4 of 5 starsInitiated CoverageStrong-Buy ➝ Equal Weight$23.005/8/2024HALOHalozyme TherapeuticsJMP Securities2 of 5 starsLower Price TargetMarket Outperform ➝ Market Outperform$72.00 ➝ $71.005/7/2024HALOHalozyme TherapeuticsHC Wainwright3 of 5 starsReiterated RatingBuy ➝ Buy$50.005/3/2024EXELExelixisHC Wainwright3 of 5 starsReiterated RatingBuy ➝ Buy$28.005/2/2024RGENRepligenJPMorgan Chase & Co.3 of 5 starsLower Price TargetOverweight ➝ Overweight$230.00 ➝ $200.005/1/2024EXELExelixisTD Cowen4 of 5 starsBoost Price TargetBuy ➝ Buy$25.00 ➝ $27.005/1/2024EXELExelixisWilliam Blair2 of 5 starsReiterated RatingOutperform4/30/2024HALOHalozyme TherapeuticsHC Wainwright3 of 5 starsReiterated RatingBuy ➝ Buy$50.004/17/2024HALOHalozyme TherapeuticsHC Wainwright3 of 5 starsReiterated RatingBuy ➝ Buy$50.004/16/2024HALOHalozyme TherapeuticsBenchmark2 of 5 starsReiterated RatingBuy ➝ Buy$50.004/11/2024EXELExelixisBarclays2 of 5 starsDowngradeOverweight ➝ Equal Weight$25.00(Data available from 5/17/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEXELExelixisN/AN/AN/AN/AN/AHALOHalozyme TherapeuticsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ASYNHSyneos HealthN/AN/AN/AN/AN/A Never Pay a Monthly Subscription Fee Again. Upgrade your MarketBeat All Access account to a lifetime subscription and lock-in these benefits for life: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Upgrade Your Account Here Questions? Have a Question? — Check out these how-to videos or send us a message: Send Message Please enter a message. Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageCustomize Your NewsletterView Current Brokerage RankingsCheck Out The Live News FeedReview Premium ReportsView The Idea Engine Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
